Harvoni (ledipasvir/sofosbuvir)

Manufacturer:
Gilead
Route of Administration: 
Oral
Site of Care:
Outpatient
Website: 
  • Manufacturer Website

Approved Indication:

treatment of chronic hepatitis C virus in adults and pediatric patients 3 years of age and older with either

  • genotype 1, 4, 5, or 6 without cirrhosis or with compensated cirrhosis
  • genotype 1 with decompensated cirrhosis in combination with ribavirin
  • genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis in combination with ribavirin

Conditions:

  • Chronic Viral Hepatitis C

Therapeutic Area:

  • Gastroenterology
  • Hepatology
  • Infectious Disease